Cedar Mountain Advisors’s BridgeBio Pharma BBIO Stock Holding History

Cedar Mountain Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.1K	Hold	149	–	–	﹤0.01%	474
2026 Q1	$11.1K	Buy	+149	New	+$10.8K	﹤0.01%	434

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Cedar Mountain Advisors's BBIO Position: Q2 2026 in Review

Cedar Mountain Advisors held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 149 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #474.

Cedar Mountain Advisors first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Cedar Mountain Advisors held 149 shares of BridgeBio Pharma worth $11.1K as of Q2 2026.
Cedar Mountain Advisors left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #474 holding.
Cedar Mountain Advisors first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.